$28.25
Price
$2.5B
Market Cap
—
P/E Ratio
16.1
Forward P/E
$-1.03
EPS (TTM)
—
Dividend Yield
$255M
Cash
$402M
Total Debt
89M
Shares Out
$12.91
$42.13
52-Week Range
Institutional Ownership of TRAVERE THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for TRAVERE THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| No activity found for this stock. | |||||
Insider Trading for TRAVERE THERAPEUTICS INC
6 Months Insider Sentiment
Buy $0
Sell $11.7M
0
Buys
17
Sells
-11.7M
Net
2
Grants
Largest
$2.8M
Dube
$2.4M
Calvin
$2.4M
Rote
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 06, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | SELL | 445 | $37.75 | $17K |
| Jan 05, 2026 | Jula Inrig | CHIEF MEDICAL OFFICER | SELL | 2.0K | $40.18 | $82K |
| Dec 24, 2025 | Jula Inrig | CHIEF MEDICAL OFFICER | EXERCISE | 15.0K | $8.93 | $134K |
| Dec 24, 2025 | William E. Rote | Chief Research Officer | SELL | 60.0K | $40.10 | $2.4M |
| Dec 24, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | SELL | 5.0K | $40.00 | $199K |
| Dec 24, 2025 | Jula Inrig | CHIEF MEDICAL OFFICER | SELL | 15.0K | $42.00 | $630K |
| Dec 24, 2025 | William E. Rote | Chief Research Officer | EXERCISE | 60.0K | $20.61 | $1.2M |
| Dec 24, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | SELL | 7.4K | $40.00 | $296K |
| Dec 15, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | SELL | 2.9K | $36.00 | $105K |
| Dec 01, 2025 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | SELL | 20.0K | $35.01 | $700K |
| Dec 01, 2025 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | EXERCISE | 20.0K | $16.23 | $325K |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | EXERCISE | 15.0K | $27.50 | $412K |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | SELL | 67.1K | $36.00 | $2.4M |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | EXERCISE | 17.5K | $26.88 | $470K |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | EXERCISE | 12.5K | $22.40 | $280K |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | EXERCISE | 10.0K | $25.25 | $252K |
| Nov 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | EXERCISE | 6.2K | $8.93 | $56K |
| Nov 03, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | GRANT | 1.1K | — | — |
| Oct 31, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | SELL | 5.6K | $35.00 | $196K |
| Oct 31, 2025 | Timothy Coughlin | Director | EXERCISE | 8.0K | $16.33 | $131K |
| Oct 31, 2025 | Timothy Coughlin | Director | EXERCISE | 10.0K | $17.44 | $174K |
| Oct 31, 2025 | Timothy Coughlin | Director | SELL | 18.0K | $35.03 | $631K |
| Oct 29, 2025 | Eric M Dube | CHIEF EXECUTIVE OFFICER | EXERCISE | 27.1K | $15.46 | $419K |
| Oct 29, 2025 | Eric M Dube | CHIEF EXECUTIVE OFFICER | SELL | 27.1K | $30.12 | $817K |
| Oct 28, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | SELL | 2.7K | $30.00 | $80K |
| Oct 28, 2025 | Eric M Dube | CHIEF EXECUTIVE OFFICER | SELL | 92.9K | $30.38 | $2.8M |
| Oct 28, 2025 | Eric M Dube | CHIEF EXECUTIVE OFFICER | EXERCISE | 92.9K | $15.46 | $1.4M |
| Sep 23, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | GRANT | 891 | — | — |
| Sep 22, 2025 | Elizabeth E Reed | Chief Legal Officer and GC | EXERCISE | 10.0K | $19.08 | $191K |
| Sep 22, 2025 | Elizabeth E Reed | Chief Legal Officer and GC | SELL | 10.0K | $25.00 | $250K |
| Sep 04, 2025 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | SELL | 119 | $19.71 | $2K |
| Sep 03, 2025 | Christopher R. Cline | CHIEF FINANCIAL OFFICER | SELL | 454 | $18.20 | $8K |